Global healthcare company Oculus Innovative Sciences has announced the allowance of a Mexican patent for use of its novel antimicrobial surgical solution in treating and preventing peritonitis. The forthcoming issuance of this patent, which will expire in 2027, will provide More Pharma (Oculus' Latin American partner) with the opportunity to pursue a new drug candidate in Latin America parallel with Ruthigen, Inc.'s (Oculus' subsidiary) development of the drug for the U.S. market. RUT58-60, the novel new formulation, is an advanced next-generation Microcyn Technology drug candidate engineered specifically for use in invasive surgical procedures, including peritonitis.
An inflammation of the peritoneum, which is the thin tissue lining the inner wall of the abdomen and covering most of the abdominal organs, peritonitis can be either localized or generalized and may result from infection (often because of hollow organ rupture, which can occur in abdominal trauma or appendicitis) or from a noninfectious process.
Once the Mexican patent has been issued, Oculus' intellectual property estate (either owned or licensed to the company) will include 36 issued patents in the United States and internationally and 109 pending applications - including U.S. provisional applications - directed to chemical compositions, apparatuses, manufacturing methods, and therapeutic uses.
More Pharma, Oculus' Mexican and Latin American partner, has additionally obtained regulatory approval for marketing the company's Microdacyn60 product family in Honduras. Oculus has separately received approval to launch a new Microcyn-based medical device in Indonesia. The company has also added two new partners in the European Union to sell the Dermacyn family of products in Finland and Serbia.
For more information, visit www.oculusis.com
Please see disclaimer on the MissionIR website